MedTrace Logo

Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

NCT05490095 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-08-05

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and safety of SVG101 (dispersible tab. of everolimus) in healthy volunteers compared to Afinitor tab. after oral administration.

Conditions

  • Pharmacokinetics

Interventions

DRUG

SVG101 (T)

5mg of SVG101

DRUG

Afinitor (R)

5mg of Afinitor

Sponsors & Collaborators

  • SoVarGen Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Eric J Maeng · SoVarGen Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-23
Primary Completion
2022-01-28
Completion
2022-02-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05490095 on ClinicalTrials.gov